Steris misses Q4 adjusted profit expectations; sets $1 bln buyback

Steris

11/05/2026 21:39

Overview

Ireland infection prevention firm's fiscal Q4 revenue rose 7% yr/yr

Q4 adjusted net income missed analyst expectations

Company authorized new $1 bln share repurchase program

Outlook

STERIS expects fiscal 2027 revenue to increase 7-8%

Company anticipates fiscal 2027 adj EPS of $11.10-$11.30

STERIS expects fiscal 2027 free cash flow of $850 mln

Result Drivers

PROCEDURE VOLUME GROWTH - Co said increased procedure volumes and a diversified customer base drove overall performance, per CEO Dan Carestio

SEGMENT REVENUE MIX - Healthcare segment revenue grew on higher service, consumables, and capital equipment sales; Life Sciences revenue rose on capital equipment, service, and consumables growth

COST PRESSURES - Operating income gains in Healthcare and Life Sciences segments were offset by tariffs and inflation

Company press release: ID:nGNX3MT8dv

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted Net Income
Miss
$278.3 mln
$283.19 mln (5 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for STERIS plc is $291.00, about 40.3% above its May 8 closing price of $207.45

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)